Nebius stock drops nearly 9% as tariff scare hits tech — Israel AI supercomputer rollout in focus

Nebius stock drops nearly 9% as tariff scare hits tech — Israel AI supercomputer rollout in focus

New York, Jan 20, 2026, 19:27 EST — After-hours

  • NBIS closed down 8.68% and edged lower in after-hours trading
  • Israel’s national AI supercomputer went live using Nebius-built infrastructure
  • Trump tariff threats over Greenland drove a broad “risk-off” move across markets

Nebius Group N.V. (NBIS.O) shares closed down 8.68% on Tuesday and slipped again in after-hours trading, in a wider tech selloff tied to fresh tariff threats. The stock ended at $99.29 and was last around $98.63 in extended hours, when trading continues after the 4 p.m. close. 1

The move matters because NBIS has become a fast-money proxy for AI data-center demand. When traders cut exposure, these names can gap and keep sliding even without a company-specific shock.

It also resets the tone into Wednesday. Investors are trying to judge whether “good news” on AI build-outs still matters in a tape that’s suddenly reacting to politics and rates, not product roadmaps.

Nebius was on screens earlier after Israel’s national AI supercomputer went live, with the cloud provider supplying the infrastructure and Nvidia B200 graphics processing units — chips widely used to train AI models — lined up for allocation, Data Center Dynamics reported. “The launch of the national supercomputer for use by industry and academia is a key step in strengthening Israel’s R&D infrastructure for artificial intelligence,” said Dror Bin, CEO of the Israel Innovation Authority. 2

The broader market, though, stayed in “risk-off” — a dash into safer assets — after U.S. President Donald Trump threatened to reignite a trade war with Europe over Greenland, according to Reuters. “The geopolitical risks that we’ve been talking about for a long time are re-emerging,” said Wasif Latif, chief investment officer at Sarmaya Partners, as the Dow fell 1.76%, the S&P 500 dropped 2.06% and the Nasdaq Composite slid 2.39%. 3

Trump said he would raise tariffs to 10% from Feb. 1 and to 25% from June 1 until the United States is allowed to buy Greenland, Reuters reported. “I’m not at the point yet where I’m willing to say this is going to precipitate a correction,” said Jamie Cox, managing partner at Harris Financial Group. 4

For Nebius, the macro shock lands on top of a capital-heavy story. A securities filing described multi-year GPU capacity agreements with Microsoft and Meta Platforms, pegging the contract values at about $17.4 billion through 2031 and about $2.9 billion over five years, respectively. 5

The stock traded between $98.34 and $104.47 on Tuesday, with about 16.6 million shares changing hands, according to StockAnalysis.com. It had closed at $108.73 on Friday, before the holiday break. 6

The volatility is not new. Investing.com shows NBIS has ranged from $18.31 to $141.10 over the past 52 weeks, a reminder that position sizes and liquidity matter as much as the headline. 7

But the risk case is easy to sketch. If tariff talk hardens into policy and bond yields keep pushing higher, the market tends to punish high-growth names that need steady funding to build capacity — even when demand looks strong.

The next company-specific catalyst is earnings. Nasdaq lists an estimated report date of Feb. 18, though companies can shift schedules, and traders will focus on any update on deployments and spending tied to Nebius’ contracted GPU build-outs. 8

Before that, the tape will likely take its cues from politics: the Brussels summit on Thursday and any follow-through from Washington, then how U.S. markets open into Wednesday after the after-hours close.

Stock Market Today

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
New York, Feb 7, 2026, 09:35 EST — Market closed. Roivant Sciences Ltd shares leapt on Friday after the company reported positive mid-stage results for its immune-modulating drug brepocitinib in a rare skin disease, and paired the readout with its quarterly financial update. The Nasdaq-listed stock closed up 22.4% at $25.82, leaving traders to gauge whether the move has legs when U.S. markets reopen on Monday, Feb. 9. It matters because Roivant is trying to turn a late-stage pipeline into approvals, and the market has been quick to reward biotechs that can show clean efficacy in controlled trials. The company
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Exxon Mobil stock holds up in tariff-driven Wall Street rout as JPMorgan lifts target
Previous Story

Exxon Mobil stock holds up in tariff-driven Wall Street rout as JPMorgan lifts target

Adobe stock price slides near 52-week low as AI video push lands and ADBE investors look to March
Next Story

Adobe stock price slides near 52-week low as AI video push lands and ADBE investors look to March

Go toTop